NYSE · MED

Medifast, Inc.

$9.73 +$0.05 (+0.52%) 1D Market open

Key Metrics

$107.63M
Market cap
P/E · TTM
$346.10M
Revenue · TTM
−$20.02M
Net income
EPS · TTM $-1.83
Dividend yield 0.1%
Free cash flow −$1.47M
Beta · 1Y 0.82
EBITDA · TTM $6.34M
Gross margin 70.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 23
    From its May 28 high, the share price fell 28%.

    Peak close $13.15 on May 28; trough close $9.45 on Jul 23. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -28%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 5
    The stock moved +22.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$107.63M
Enterprise value
Shares outstanding11.1M
52-wk range$9.22 – $15.11
Avg volume · 20D210.7K
Net cash
Book value / share$18.06
IndustryMiscellaneous Food Preparations & Kindred Products
ExchangeNYSE
About Medifast, Inc.
IPO dateMar 24, 1981
Employees380

Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.31
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 70.1%
Operating -2.3%
Net -5.8%
FCF -0.4%
ROE / ROIC -9.8% · -69.7%

Financial Health

Current ratio4.80
Quick ratio4.30
Debt / equity
Debt / EBITDA
Net cash
Working capital$160.45M

Cash Flow · TTM

Operating CF $3.72M
Capex −$5.19M
Free cash flow −$1.47M
Buybacks
Dividends paid $88.00K
Shareholder yield 0.1%

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

4.1
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings